Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of sapablursen in polycythemia vera
2025-524669-25-00Phase 3Authorised
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Sep 2026
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in polycythemia vera (PV) comparing Sapablursen with Placebo (2 arms). Primary endpoint: Number of phlebotomies from Week 0 through Week 32 and hematocrit control through Week 32. Planned start Sep 2026; status: authorised.
02
Drugs
sapablursen
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2025-524669-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524669-25-00.